Global Oncology Biosimilars Market Overview:
Cancer is attributed as the second leading cause of fatalities across the world. According to the World Health Organization, an estimated 9.6 million deaths occurred in 2018. Naturally, pharmaceutical companies have boosted cancer treatment drugs production to cater to such a large pool of patients. Since blockbuster biologic drugs are quite expensive, the stage is set for the entry of biosimilar and generic drugs. Based on these trends, the oncology biosimilars market is looking at a bright future ahead expanding at a stellar CAGR of 29.4% by 2025 end.
The ongoing COVID-19 pandemic, however, is anticipated to inhibit progress in the short-run. Supply shortages, owing to nationwide lockdowns across emerging economies, are anticipated to occur. Likewise, the shifted focus of healthcare providers to care for COVID-19 patients are poised to delay evaluation and uptake of biosimilar drugs. This is because healthcare providers would prefer to stick to the status quo therapy options and proceed with existing drugs. Moreover, delays in biosimilar clinical trials are further anticipated to limit growth prospects in the near-term. However, post-COVID-19, the global oncology biosimilars market shall experience a resurgence.
Global Oncology Biosimilars Market Analysis by Disease Indication:
The blood cancers segment is projected to expand the fastest, at a whopping 33.0% CAGR during the forecast period. This is mostly attributed to a rising number of novel drugs in the pipeline of key manufacturers. The blood cancers segment is anticipated to capture more than 1/5th of the total oncology biosimilars market.
However, the neutropenia segment is poised to dominate the global oncological biosimilars market, capturing more than half of the total market share. Expiration of patented blockbuster biologics has paved way for increased usage of biosimilar products in the segment. In 2018, the FDA approved the use of filgrastim-aafi manufactured by Pfizer, for treating neutropenia among patients who have undergone blood cancer treatment. The neutropenia segment is anticipated to expand at a dexterous CAGR of 29.6%.
Get the latest COVID-19 impact insights on the oncology biosimilars market, by asking an analyst here
Global Oncology Biosimilars Market Regional Insights:
The Asia-Pacific oncology biosimilars market is set to register aggrandizing growth, expanding at a CAGR of 30.7%, thus reaching a position of market dominance. The Asia-Pacific market is poised to capture more than one-third of the overall market. This impressive growth trajectory is attributed to active collaboration within market giants to expand profit pools. For instance, in 2016, Dr. Reddy’s Laboratories collaborated with TR-Pharm to commercialize the former’s three biosimilars in Turkey.
Access our cutting-edge regional insights on the oncology biosimilars market by requesting for a report sample here
North America presents equally lucrative growth opportunities. Burgeoning investment in research and development to develop pipeline portfolios is a key growth driver of the region. Biocon, a leading Indian pharmaceutical company, owns three pipeline biosimilars in the oncology segment. Apotex Inc. has five biosimilars in its pipeline. Together, the companies have introduced these drugs into the market. The North American oncology biosimilars market is set to expand at a CAGR of 32.0%, capturing over a quarter of the market.
Global Oncology Biosimilars Market Companies’ Strategies
The global oncology biosimilars market consists of the following market players: Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., Biocon, Teva Pharmaceutical Industries Ltd., and Sandoz International GmBh. This makes it a highly consolidated market. Collectively, these market players account for more than 70% of the market share. In order to broad based their market footprints, these companies rely heavily on strengthening their product distribution networks through active collaborations.
Biocon, for instance, announced an exclusive global collaboration with Sandoz on next-generation biosimilars in 2018. Likewise, Dr. Reddy’s collaborated with TR Pharm to launch three biosimilars in Turkey in 2016. Other prominent market players in the global oncology biosimilars market include Pfizer, Inc., Celltrion, Inc., Sandoz International GmBh, STADA Arzneimittel AG and Apotex, Inc. to name a few.
COVID-19’s Impact on Oncology Biosimilars Market:
The ongoing COVID-19 pandemic has brought the world to a standstill. With business operations getting suspended, industries are facing supply chain disruptions and a subsequent demand-supply gap. With regard to oncology biosimilars, the market is anticipated to register a decline in the short-run. This is attributed to shifting priorities of healthcare providers towards addressing patients with acute COVID-19 infections. Delays in clinical trials are anticipated, owing to this, which will eventually delay product launches. Fortunately, providers are looking for options to compensate for the extra expenses they are incurring at the present moment. It will become more important than ever for biosimilars to deliver on their promise of bringing savings to the healthcare system.
Analyst’s Viewpoint:
The global oncology biosimilars market is set to embark on a positive growth path throughout the forecast period. Blockbuster generic drugs have now reached a cliffhanger, anticipated to soon phase out. This is providing immense opportunities for companies operating in this market to expand their product portfolios. Moreover, lucrative opportunities exist in the Asia-Pacific, owing to presence of important market players as well as increasing cancer cases attributed to sedentary lifestyles.
Global Oncology Biosimilars Market: Report Scope:
The recent study on oncology biosimilars published by Fact.MR incorporates a 5-year forecast period from 2020 to 2025 and explicates on vital dynamics such as the key drivers, opportunities and restraints for the market. The report analyses the market based on the following segments: drug class, disease indication and distribution channel. Each segment includes a detailed analysis in terms of market share, revenue and overall growth.
A section on regional analysis has been included based on the following four geographies: North America, Europe, Asia-Pacific and Rest of the World. Each region has been analyzed based on the aforementioned segments.
Global Oncology Biosimilars Market- Scope of the Report
The recent study by Fact.MR on the global oncology biosimilars market offers a 5-year forecast between 2020 and 2025. The study analyzes crucial trends currently determining the growth of the market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders and emerging players associated with the production of oncology biosimilars products. The study also provides dynamics responsible for influencing the future status of the global oncology biosimilars market over the forecast period.
A detailed assessment of the global oncology biosimilars market’s value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global oncology biosimilars market along with their product portfolio enhances the reliability of this comprehensive research study.
Global Oncology Biosimilars Market: Report Summary
The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in the global oncology biosimilars market across the globe.
A comprehensive estimate on the global oncology biosimilars market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of global oncology biosimilars market during the forecast period.
Global Oncology biosimilars Market Segmentation
Fact.MR has studied the global oncology biosimilars market with detailed segmentation on the basis of drug class, disease indication, distribution channel and region.
|
Drug Class |
Disease Indication |
Distribution Channel |
Region |
|
G-CSF |
Breast Cancer |
Hospital Pharmacy |
North America |
|
Monoclonal Antibody |
Non-Small Cell Lung Cancer |
Retail Pharmacy |
Europe |
|
Hematopoietic Agents |
Colorectal Cancer |
Online Pharmacy |
Asia Pacific |
|
|
Neutropenia |
|
Rest of the World |
|
|
Blood Cancer: Leukemia: Myeloid Leukemia Chronic Lymphocytic Leukemia (CLL) Others
Non-Hodgkin Lymphoma |
|
|
|
|
Others |
|
|
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”
Global Oncology Biosimilars Market: Analysis on Market Size Evaluation
The global oncology biosimilars market has been analyzed for each market segment, in terms of value (US$ Mn).
Market estimates at global and regional levels for global oncology biosimilars market is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent global oncology biosimilars market segments, along with market attractiveness evaluation has been incorporated in the report.
Global Oncology Biosimilars Market: Inspected Assessment on Regional Segments
Key sections have been elaborated in the global oncology biosimilars report, which have helped deliver projections on the regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of the global oncology biosimilars market during the forecast period.
Country-specific valuation on demand for global oncology biosimilars has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value for emerging countries has also been included in the report.
Global Oncology Biosimilars Market: In-Depth Analysis on Competitive Landscape
The report sheds light on the leading manufacturers of global oncology biosimilars products along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of global oncology biosimilars products, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, such as product portfolio, key strategies along with an all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the global oncology biosimilars market. Prominent manufacturers with established market presence in the global oncology biosimilars market are Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., Biocon, Teva Pharmaceutical Industries Ltd., and Sandoz International GmBh.
Section 01. Preface
1.1. Market Definition and Scope
1.2. Research Highlights
Section 02. Assumptions and Research Methodology
2.1. Assumptions & Acronyms Used
2.2. Research Methodology
Section 03. Executive Summary: Global Oncology Biosimilar Market
3.1. Executive Summary
3.2. Market Opportunity Map
3.3. Market Overview
3.4. Key Industry Developments
3.5. Global Oncology Biosimilar Market Size (US$ Mn) Forecast, 2020–2025
3.6. Global Oncology Biosimilar Market Outlook
Section 04. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunity
4.4. Key Trends
Section 05. Porter’s Five Force Analysis
Section 06. Oncology Biosimilars: Key Molecules
Section 07. Biosimilars Market Snapshot
Section 08. Cancer Statistics
Section 09. Global Oncology Biosimilars Market Analysis and Forecasts, By Drug Class
9.1. Introduction & Definition
9.2. Key Findings
9.3. Global Oncology Biosimilars Market Value Share, by Drug Class, 2020 and 2025
9.4. Market Attractiveness by Drug Class
9.5. Global Oncology Biosimilars Market Forecast, by Drug Class, 2020-2025
9.5.1. G-CSF
9.5.2. Monoclonal Antibody
9.5.3. Hematopoietic Agents
9.6. Global Oncology Biosimilars Market Analysis, by Drug Class, 2020-2025
9.7. Key Trends
Section 10. Global Oncology Biosimilars Market Analysis and Forecasts, By Disease Indication
10.1. Introduction & Definition
10.2. Key Findings
10.3. Global Oncology Biosimilars Market Value Share, by Disease Indication, 2020 and 2025
10.4. Market Attractiveness By Disease Indication
10.5. Global Oncology Biosimilars Market Forecast, by Disease Indication, 2020-2025
10.5.1. Breast Cancer
10.5.2. Non-Small Cell lung Cancer
10.5.3. Blood Cancer
10.5.3.1. Leukemia
10.5.3.1.1. Myeloid Leukemia
10.5.3.1.2. Chronic Lymphocytic Leukemia
10.5.3.1.3. Others
10.5.3.2. Non-Hodgkin Lymphoma
10.5.4. Colorectal Cancer
10.5.5. Neutropenia
10.5.6. Others
10.6. Global Oncology Biosimilars Market Analysis, by Disease Indication, 2020-2025
10.7. Key Trends
Section 11. Global Oncology Biosimilars Market Analysis and Forecasts, By Distribution Channel
11.1. Introduction & Definition
11.2. Key Findings
11.3. Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2020 and 2025
11.4. Market Attractiveness By Distribution Channel
11.5. Global Oncology Biosimilars Market Forecast, by Distribution Channel, 2020-2025
11.5.1. Hospital Pharmacy
11.5.2. Online Pharmacy
11.5.3. Retail Pharmacy
11.6. Global Oncology Biosimilars Market Analysis, by Distribution Channel, 2020-2025
11.7. Key Trends
Section 12. Global Oncology Biosimilars Market Analysis and Forecasts, By Region
12.1. Global Market Scenario
12.2. Global Oncology Biosimilars Market Value Share, by Region, 2020 and 2025
12.3. Global Oncology Biosimilars Market Attractiveness, by Region, 2020–2025
12.4. Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2020–2025
12.4.1. North America
12.4.2. Europe
12.4.3. Asia Pacific
12.4.4. Rest of the World
Section 13. North America Oncology Biosimilars Market Analysis and Forecast
13.1. North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020–2025
13.2. North America Oncology Biosimilars Market Value Share, by Country, 2020 and 2025
13.3. North America Oncology Biosimilars Market Attractiveness, by Country, 2020–2025
13.4. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2020–2025
13.4.1. U.S.
13.4.2. Canada
13.5. North America Oncology Biosimilars Market Value Share, by Drug Class, 2020 and 2025
13.6. North America Oncology Biosimilars Market Attractiveness, by Drug Class, 2020–2025
13.7. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2020–2025
13.7.1. G-CSF
13.7.2. Monoclonal Antibody
13.7.3. Hematopoietic Agents
13.8. North America Oncology Biosimilars Market Value Share, by Disease Indication, 2020 and 2025
13.9. North America Oncology Biosimilars Market Attractiveness, by Disease Indication, 2020–2025
13.10. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2020–2025
13.10.1. Breast Cancer
13.10.2. Non-Small Cell lung Cancer
13.10.3. Blood Cancer
13.10.3.1. Leukemia
13.10.3.1.1. Myeloid Leukemia
13.10.3.1.2. Chronic Lymphocytic Leukemia
13.10.3.1.3. Others
13.10.3.2. Non-Hodgkin Lymphoma
13.10.4. Colorectal Cancer
13.10.5. Neutropenia
13.10.6. Others
13.11. North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2020 and 2025
13.12. North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2020–2025
13.13. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2025
13.13.1. Hospital Pharmacy
13.13.2. Online Pharmacy
13.13.3. Retail Pharmacy
13.14. Key Trends
Section 14. Europe Oncology Biosimilars Market Analysis and Forecast
14.1. Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020–2025
14.2. Europe Oncology Biosimilars Market Value Share, by Country, 2020 and 2025
14.3. Europe Oncology Biosimilars Market Attractiveness, by Country, 2020–2025
14.4. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2020–2025
14.4.1. U.K.
14.4.2. Germany
14.4.3. France
14.4.4. Italy
14.4.5. Russia
14.4.6. Spain
14.4.7. Rest of Europe
14.5. Europe Oncology Biosimilars Market Value Share, by Drug Class, 2020 and 2025
14.6. Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2020–2025
14.7. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2020–2025
14.7.1. G-CSF
14.7.2. Monoclonal Antibody
14.7.3. Hematopoietic Agents
14.8. Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2020 and 2025
14.9. Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2020–2025
14.10. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2020–2025
14.10.1. Breast Cancer
14.10.2. Non-Small Cell lung Cancer
14.10.3. Blood Cancer
14.10.3.1. Leukemia
14.10.3.1.1. Myeloid Leukemia
14.10.3.1.2. Chronic Lymphocytic Leukemia
14.10.3.1.3. Others
14.10.3.2. Non-Hodgkin Lymphoma
14.10.4. Colorectal Cancer
14.10.5. Neutropenia
14.10.6. Others
14.11. Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2020 and 2025
14.12. Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2020–2025
14.13. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2025
14.13.1. Hospital Pharmacy
14.13.2. Online Pharmacy
14.13.3. Retail Pharmacy
14.14. Key Trends
Section 15. Asia Pacific Oncology Biosimilars Market Analysis and Forecast
15.1. Asia Pacific Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020–2025
15.2. Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2020 and 2025
15.3. Asia Pacific Oncology Biosimilars Market Attractiveness, by Country, 2020–2025
15.4. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2020–2025
15.4.1. China
15.4.2. India
15.4.3. Japan
15.4.4. Australia & New Zealand
15.4.5. Rest of Asia Pacific
15.5. Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2020 and 2025
15.6. Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2020–2025
15.7. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2020–2025
15.7.1. G-CSF
15.7.2. Monoclonal Antibody
15.7.3. Hematopoietic Agents
15.8. Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2020 and 2025
15.9. Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2020–2025
15.10. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2020–2025
15.10.1. Breast Cancer
15.10.2. Non-Small Cell lung Cancer
15.10.3. Blood Cancer
15.10.3.1. Leukemia
15.10.3.1.1. Myeloid Leukemia
15.10.3.1.2. Chronic Lymphocytic Leukemia
15.10.3.1.3. Others
15.10.3.2. Non-Hodgkin Lymphoma
15.10.4. Colorectal Cancer
15.10.5. Neutropenia
15.10.6. Others
15.11. Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2020 and 2025
15.12. Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2020–2025
15.13. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2025
15.13.1. Hospital Pharmacy
15.13.2. Online Pharmacy
15.13.3. Retail Pharmacy
15.14. Key Trends
Section 16. Rest of the World Oncology Biosimilars Market Analysis and Forecast
16.1. Rest of the World Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020–2025
16.2. Rest of the World Oncology Biosimilars Market Value Share, by Country, 2020 and 2025
16.3. Rest of the World Oncology Biosimilars Market Attractiveness, by Country, 2020–2025
16.4. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2020–2025
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of the World
16.5. Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2020 and 2025
16.6. Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2020–2025
16.7. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2020–2025
16.7.1. G-CSF
16.7.2. Monoclonal Antibody
16.7.3. Hematopoietic Agents
16.8. Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2020 and 2025
16.9. Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2020–2025
16.10. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2020–2025
16.10.1. Breast Cancer
16.10.2. Non-Small Cell lung Cancer
16.10.3. Blood Cancer
16.10.3.1. Leukemia
16.10.3.1.1. Myeloid Leukemia
16.10.3.1.2. Chronic Lymphocytic Leukemia
16.10.3.1.3. Others
16.10.3.2. Non-Hodgkin Lymphoma
16.10.4. Colorectal Cancer
16.10.5. Neutropenia
16.10.6. Others
16.11. Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2020 and 2025
16.12. Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2020–2025
16.13. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2025
16.13.1. Hospital Pharmacy
16.13.2. Online Pharmacy
16.13.3. Retail Pharmacy
16.14. Key Trends
Section 17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2018)
Section 18. Company Profiles
18.1. Sandoz International GmbH
18.1.1. Company Details
18.1.2. Business Overview
18.1.3. Financial Overview
18.1.4. Strategic Overview
18.1.5. SWOT Analysis
18.2. Pfizer, Inc.
18.2.1. Company Details
18.2.2. Business Overview
18.2.3. Financial Overview
18.2.4. Strategic Overview
18.2.5. SWOT Analysis
18.3. Celltrion Inc.
18.3.1. Company Details
18.3.2. Business Overview
18.3.3. Financial Overview
18.3.4. Strategic Overview
18.3.5. SWOT Analysis
18.4. Dr. Reddy’s Laboratories Ltd.
18.4.1. Company Details
18.4.2. Business Overview
18.4.3. Financial Overview
18.4.4. Strategic Overview
18.4.5. SWOT Analysis
18.5. Biocon
18.5.1. Company Details
18.5.2. Business Overview
18.5.3. Financial Overview
18.5.4. Strategic Overview
18.5.5. SWOT Analysis
18.6. Teva Pharmaceutical Industries Ltd.
18.6.1. Company Details
18.6.2. Business Overview
18.6.3. Financial Overview
18.6.4. Strategic Overview
18.6.5. SWOT Analysis
18.7. STADA Arzneimittel AG
18.7.1. Company Details
18.7.2. Business Overview
18.7.3. Financial Overview
18.7.4. Strategic Overview
18.7.5. SWOT Analysis
18.8. Apotex Inc. (Apobiologix)
18.8.1. Company Details
18.8.2. Business Overview
18.8.3. Financial Overview
18.8.4. Strategic Overview
18.8.5. SWOT Analysis
18.9. Intas Pharmaceuticals Ltd.
18.9.1. Company Details
18.9.2. Business Overview
18.9.3. Financial Overview
18.9.4. Strategic Overview
18.9.5. SWOT Analysis
18.10. BIOCAD
18.10.1. Company Details
18.10.2. Business Overview
18.10.3. Financial Overview
18.10.4. Strategic Overview
18.10.5 SWOT Analysis
Fact.MR offers custom research services that help clients to get specific research solutions
Related reports
We are committed towards customer satisfaction and quality service.
Our Clients
Fact.MR in Media
Our analysts in Media
Oncology Biosimilars Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025